CD33 and acute myeloid leukemia: Nonetheless, current clinical trials underway in relapsed/refractory AML include CD33, CD38, CD123, and CD19 CAR-T cell therapies, allogenic CAR NK-cells, and CD33xCD3 and CD123xCD3 bispecific antibodies[11,41].